Brief: Protalix Biotherapeutics And Partner Chiesi Global Rare Diseases And Announce FDA Approval Of Genetic Disorder Therapy
10/05/2023 12:22
May 10 (Reuters) - Protalix Biotherapeutics Inc
PBDA.F :
* CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS
ANNOUNCE FDA APPROVAL OF ELFABRIO® (PEGUNIGALSIDASE ALFA-IWXJ)
FOR THE TREATMENT OF FABRY DISEASE
Source text for Eikon: ID:nPn4M8j01a
Further company coverage: PBDA.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio